Intellia Therapeutics

YTD

ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

CEO

John M. Leonard

CEOJohn M. Leonard

Employees

377

Employees377

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2014

Founded2014

Employees

377

Employees377

NTLA Key Statistics

Market cap

1.91B

Market cap1.91B

Price-Earnings ratio

-3.87

Price-Earnings ratio-3.87

Dividend yield

—

Dividend yield—

Average volume

6.97M

Average volume6.97M

High today

$14.15

High today$14.15

Low today

$12.85

Low today$12.85

Open price

$13.35

Open price$13.35

Volume

14.83M

Volume14.83M

52 Week high

$28.25

52 Week high$28.25

52 Week low

$6.83

52 Week low$6.83

Stock Snapshot

As of today, Intellia Therapeutics(NTLA) shares are valued at $13.50. The company's market cap stands at 1.91B, with a P/E ratio of -3.87.

On 2026-05-16, Intellia Therapeutics(NTLA) stock moved within a range of $12.85 to $14.15. With shares now at $13.50, the stock is trading +5.1% above its intraday low and -4.6% below the session's peak.

Trading activity shows a volume of 14.83M, compared to an average daily volume of 6.97M.

The stock's 52-week range extends from a low of $6.83 to a high of $28.25.

NTLA News

Simply Wall St 1d

A Look At Intellia Therapeutics Valuation After Recent Gene Editing Trial And BLA Progress

Intellia Therapeutics (NTLA) is back in focus after reporting positive Phase 3 HAELO results for lonvo-z in hereditary angioedema, as well as starting a rolling...

Simply Wall St 2d

Earnings Update: Intellia Therapeutics, Inc. Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Intellia Therapeutics, Inc. ( ) defied analyst predictions to release its quarterly results, which were ahead of market expectations. It looks like a positive r...

TipRanks 3d

Intellia Therapeutics price target raised to $17 from $13 at Bernstein

Bernstein raised the firm’s price target on Intellia Therapeutics (NTLA) to $17 from $13 and keeps a Market Perform rating on the shares. Biotech has had a stro...

Analyst ratings

50%

of 24 ratings

Buy

50%

Hold

41.7%

Sell

8.3%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.